tirilazad mesylate

Small moleculeexperimental

Clinical trial activity

1 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0

Earliest trial started Dec 1, 1991 (NCT00004759)

Timeline

1990s

  1. Jan 1, 1991

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetOTHER

    Lipid peroxidation inhibitor

    Lipid peroxidation inhibitor (radical scavenging and membrane stabilizing).

  • Unspecified targetAntioxidant

    antioxidant

Chemistry & pharmacology

Loading structure…

SMILES

C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1
Mol. weight
624.87 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 21-(4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl)-16-methylpregna-1,4,9(11)-triene-3,20-dione monomethane sulfonate
  • freedox
  • freedox
  • pregna-1,4,9(11)-triene-3,20-dione, 21-(4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl)-16-methyl-, (16alpha)-, monomethanesulfonate
  • tirilazad
  • tirilazad
  • tirilazad
  • tirilazad
  • tirilazad
  • tirilazad
  • tirilazad
  • tirilazad mesilate
  • tirilazad mesylate
  • tirilazad mesylate
  • tirilazad mesylate
  • tirilazad mesylate
  • tirilazad mesylate
  • tirilazad mesylate hydrate
  • u-74006
  • u74006f
  • u 74006f
  • u-74006f

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00004759Phase 3Dec 1, 1991National Institute of Neurological Disorders and Stroke (NINDS), Yale University
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Institute of Neurological Disorders and Stroke (NINDS)Government1111991
Yale UniversityAcademic/Hospital1011991
2 organizations
Page 1 / 1